United Therapeutics Signs Deal With DEKA For New Remodulin Delivery System

(RTTNews) - United Therapeutics Corp. (UTHR) said it has signed an agreement with DEKA Research & Development Corp. for the development of a potential technology breakthrough in the subcutaneous delivery of Remodulin or treprostinil Injection to patients with pulmonary arterial hypertension via a pre-filled semi-disposable pump system. Financial terms of the agreement were not announced.

United Therapeutics expects to introduce the new subcutaneous Remodulin delivery system in the 2016-2018 timeframe.

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension or PAH to diminish symptoms associated with exercise.